Anonymous
Guest
Anonymous
Guest
They have produced . . . . . excuses on CP!
I really do like Donald John's excuses. They are the best.
They have produced . . . . . excuses on CP!
I really do like Donald John's excuses. They are the best.
For his excuses he uses the best practices from the rest of the industry.
When's the shutdown????
this would be credible if it came from a scientist in an organization with any scientific credibility - nibr is a laughing stock both in the eyes of academia as well as industry research organizations. it's like a professor from a 3rd rate university talking about how a good university should be run. until you get more results you can say all you want but no one will listen.
------------------------------
Speaking as someone who was absorbed (for lack of a better term) into NIBR due to NVS acquisition of my former employer? I have to agree with the original post. We previously had a solid track record of turning out new drug entities and had quite a few very promising projects in the works. Those projects were rapidly killed by NIBR management because they (the projects) did not fit with the NIBR "vision" (read: management's pet projects), whatever that may be. Our experience and expertise meant nothing to our new overlords. Personnel were cut, projects were dumped, morale was lost. And our original, viable and robust pipeline met the same fate as the banana peel you tossed into yesterday's trash.
So, yes, I do blame management. Thanks for letting me vent despite that I'm not a sales rep, but simply one of your reviled research personnel.